EWTX

SEC source: 0001562180-22-004887 · primarydocument.xml · derivative · entry 10

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,894

Underlying: Common Stock · 13,934 shares

Expires 2030-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 4

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 3

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-004887 · primarydocument.xml · derivative · entry 9

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,828

Underlying: Common Stock · 15,230 shares

Expires 2030-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 2

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,230

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.

F2 · balance_after: Includes 1,438 shares purchased on May 16, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-22-004407 · primarydocument.xml · derivative · entry 2

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,122

Underlying: Common Stock · 9,000 shares

Expires 2030-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-004407 · primarydocument.xml · nonDerivative · entry 1

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,562 shares purchased on November 15, 2021 and 1,438 shares purchased on May 15, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0000947871-22-000629 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 13,497,456

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in multiple transactions at prices ranging from $7.04 to $7.24. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI.

F4 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated Peter A. Thompson ("Thompson"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Thompson, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-22-000628 · ownership.xml · nonDerivative · entry 1

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 13,497,456

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in multiple transactions at prices ranging from $7.04 to $7.24. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI.

F4 · ownership.nature: Each of the Reporting Person, GP VI, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors has designated the Reporting Person, a member of of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Person, GP VI, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001562180-22-004201 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $7.11 to $8.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 1,438 shares purchased on May 16, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-22-003664 · primarydocument.xml · derivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,625

Underlying: Common Stock · 15,625 shares

Expires 2025-05-01

F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-22-003666 · primarydocument.xml · derivative · entry 1

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,625

Underlying: Common Stock · 15,625 shares

Expires 2025-05-01

F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-22-003667 · primarydocument.xml · derivative · entry 1

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,625

Underlying: Common Stock · 15,625 shares

Expires 2025-05-01

F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-22-003665 · primarydocument.xml · derivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,625

Underlying: Common Stock · 15,625 shares

Expires 2025-05-01

F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-22-003663 · primarydocument.xml · derivative · entry 1

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 31,250 shares

Expires 2025-05-01

F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-22-003662 · primarydocument.xml · derivative · entry 1

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 31,250 shares

Expires 2025-05-01

F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001062993-22-005965 · form4.xml · nonDerivative · entry 1

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by USVP XI

Disclosed balance after: 0

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners XI, L.P. without additional consideration to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners XI, L.P. without additional consideration to its partners.

F2 · ownership.nature: These securities are held of record by U.S. Venture Partners XI, L.P. (''USVP XI''). Presidio Management Group XI, L.L.C. ("PMG XI"), the general partner of USVP XI, has sole voting and dispositive power with respect to the shares held by USVP XI. The Reporting Person is a managing member of PMG XI with additional rights with respect to the issuer's securities, and may be deemed to have sole voting and dispositive power with respect to such shares. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

SEC source: 0001562180-22-000645 · primarydocument.xml · derivative · entry 2

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,322

Underlying: Common Stock · 5,400 shares

Expires 2030-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-000645 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,362

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-21-007920 · primarydocument.xml · derivative · entry 2

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,722

Underlying: Common Stock · 5,400 shares

Expires 2030-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-21-007920 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,962

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,562 shares purchased on November 15, 2021 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-21-007369 · primarydocument.xml · derivative · entry 4

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,352

Underlying: Common Stock · 25,000 shares

Expires 2028-08-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vested on September 10, 2018 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-21-007369 · primarydocument.xml · derivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 147,585 shares

Expires 2027-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 1/4th of the shares subject to the option vested on July 27, 2018 and 1/48th of the shares subject to the option vested each month thereafter.

SEC source: 0001562180-21-007369 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,585

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-21-007369 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,585

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-21-007134 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001562180-21-007134 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.56 to $19.52, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 7

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 479

F8 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.01 to $19.89, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 6

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,041

F7 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.29 to $20.82, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 5

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,722

F6 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.29 to $20.285, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 4

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,317

F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.16 to $20.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,897

F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.095 to $20.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,643

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.17 to $20.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,355

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.17 to $20.165, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006901 · primarydocument.xml · nonDerivative · entry 4

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,219

F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.84 to $20.645, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006901 · primarydocument.xml · nonDerivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,236

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.25 to $20.19, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006901 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,272

SEC source: 0001562180-21-006901 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,278

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.43 to $20.415, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 5

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,670

F6 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.36 to $19.53, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 4

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,789

F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.345 to $19.34, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,032

F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.325 to $18.32, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,854

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.025 to $17.995, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,373

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006498 · primarydocument.xml · nonDerivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,842

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.

SEC source: 0001562180-21-006498 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,968

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006498 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,275

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006455 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,024

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006391 · primarydocument.xml · nonDerivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,294

F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.71, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-21-006391 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,196

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.62, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.